Development↦Management↦Informed Consent Process↦Procedures
What is it? Why is it important?
The Informed Consent Process (ICP) describes procedures used to obtain participant:
- Consent for study participation
- Re-consent for study participation during study conduct (i.e. due to changes potentially affecting participant willingness to remain in the study)
The key steps in the ICP are to:
- Assess the participant’s eligibility (e.g. compliance with study inclusion & exclusion criteria)
- Hand out the Participant Information Sheet (PIS) and explain the study to the participant (e.g. study design, intervention, safety issues, time investment, further-use of study data and biological material)
- Answer questions the participant may have, and to provide the participant with ample time to decide on study participation
- Sign and date an Ethics Committee (EC) approved Informed Consent Form (ICF), once the participant has agreed to participate in the study
- Provide the participant with a signed copy of the ICF
- Document study inclusion in the patient file and the study database
- File the ICF in the ISF
More
The implementation of an ICP can face increasing challenges due to:
- The target population of the study (e.g. healthy volunteers, pregnant women, children, adolescents, persons unable to give consent)
- The complexity of the study (e.g. placebo controlled studies, emergency situations, inclusion of legal representatives)
- Increased study risks (e.g. first in man, intervention with novel drugs lacking extensive safety profiles, vulnerable target population)
- The collection of biological material and health related persona data for further-use projects
In the event of a substantial amendment during study conduct, participants should:
- Be informed about the changes including potential consequences (e.g. additional safety concerns, sampling of biological material, visits, data collection, and time investments)
- Re-consent to amended study procedures by dating and signing an updated ICF, approved by the EC
What do I need to do?
As a SP-INV, describe:
- ICP procedures applicable to your study in an SOP or study protocol
- Means on how to inform and obtain consent (e.g. in writing and/or orally, exemption from the written form)
- How to document consent (e.g. in patient file, study database)
- The timing of consent (e.g. with study procedures planned the same day, or post-hoc, incomplete information, step-wise consent)
- How to document ICP deviations (e.g. note to file)
Additional aspects to include:
- The use of advertisement
- Participant remuneration procedures
- Handling of data and biological material from participants who withdrew from the study, or were lost to follow-up
To ensure that the ICP is correctly implemented during study conduct, ensure that:
- Study staff remains trained on the SOP and are informed about potential changes
- Study staff authorized to carry out the ICP are defined in a delegation log
- Only EC approved documents (ICF, PIS) are used (e.g. document management)
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
External Links
Swissethics – see in particular:
- Checklist for the recruitment of study participants by means of advertising
- Specimen text for advertisement
- Guidelines on the retention period of biological material and personal data of further-use projects without consent
- Conception and application of an electronic informed consent
- Time for consideration
- Monetary contributions to patients participating in research projects
References
ICH GCP E6(R2) – see in particular guideline
- 4.8. Informed consent of trial subjects
Declaration of Helsinki – see in particular principles
- 25 – 32 Informed Consent
ISO 14155:2020 Medical devices (access liable to costs) - see in particular sections
- 5.8 Informed consent
Swiss Law
HRA – see in particular articles and chapters
- Art. 16 Informed consent
- Art. 17 Consent to further use for research
- Art. 18 Incomplete consent
- Chapter 3, section 1. Research involving children, adolescents, adults lacking capacity.
- Chapter 3, section 2. Research involving pregnant women, IFV embryos, foetuses
- Chapter 3, section 3. Research involving prisoners
- Chapter 3, section 4. Research in emergency situation
ClinO – see in particular articles
- Art. 7 Informed Consent
- Art. 8 Exception to the written form
- Art. 9 Consequences of revocation of consent
- Art. 15 Post hoc consent in emergency situations
HRO – see in particular articles and chapter
- Art. 8 Informed Consent
- Art. 9 Exception to the written form
- Art. 10 Consequences of revocation of consent
- Art.11 Research projects in emergency situations
- Art. 41 Research involving deceased persons
- Art. 44 Informed consent involving embryos and foetuses
- Chapter 3, section 2. Informed consent and information in further use of biological material and health-related data